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Prostaglandin E1 was administered by means of coro-
nary venous synchronized retroperfusion and the effec-
tiveness of the combined (prostaglandin-retroperfusion)
system was examined during acute myocardial ischemia
in 10 closed chest anesthetized dogs. Such treatment was
administered between 30 minutes and 3 hours after oc-
clusion of the proximal left anterior descending coronary
artery. An equivalent series of 10 dogs with arterial
blood retroperfusion alone and 9 untreated dogs served
as control subjects. Standardized two-dimensional echo-
cardiographic measurements of global and regional left
ventricular function were performed in five short-axis
cross sections. The global low left ventricular section and
its profoundly ischemic anterolateral region exhibited
distinctly improved systolic fractional area changes as a
result of the prostaglandin E1 retroperfusion treatment
between 30 minutes and 3 hours after occlusion (22.9 ±
1.5 to 41.2 ± 4.0% and 1.8 ± 3.6 to 29.4 ± 5.6%,
respectively). In contrast, further deterioration in func-
tion was noted during an untreated equivalent coronary
Prostaglandin E) has been reported to provide direct myo-
cardial benefits in acute ischemia, by virtue of coronary
vasodilation along with possibly enhanced myocardial con-
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occlusion period (16.3 ± 2.7 to 10.0 ± 3.3% and 12.6
± 6.1 to 4.1 ± 6.9%). Although arterial blood retro-
perfusion alone provided distinct benefits in the ischemic
region of a midpapillary echo section (from 13.4 ± 3.9
to 32.1 ± 10.4%, P < 0.05), no improvements were
observed in profoundly jeopardized segments at the low
left ventricular level (5.6 ± 6.0 to 0.9 ± 5.7%).
Triphenyltetrazolium chloride delineation of infarc-
tion revealed significant myocardial salvage with pros-
taglandin E. retroperfusion as compared with findings
in untreated control dogs (3.7% ± 1.3% of the left
ventricle versus 9.3 ± 1.9%, p < 0.05). The respective
ratios of necrosis to glycogen-depleted ischemic zones in
a mid-left ventricular slab were 19.5 ± 6.4% versus
47.1 ± 8.9 (p < 0.05).
It is concluded that retrograde prostaglandin E.
administration may further enhance the effectiveness of
synchronized coronary venous retroperfusion treatment
of jeopardized acutely ischemic myocardium.
tractility and counteraction on platelet aggregation (\ -4).
Synchronized coronary venous retroperfusion provides an
alternative route to delivery of arterial blood or pharma-
cologic agents to otherwise poorly accessible zones distal
to a coronary occlusion (5-12). The current experimental
study examined the effectiveness of administering prosta-
glandin E , by synchronized retroperfusion as a means for
treatment of profoundly jeopardized ischemic myocardium
after acute coronary artery occlusions.
Methods
Experimental preparation. Twenty-nine adult dogs
weighing 20 to 30 kg were premedicated with morphine
sulfate (1.5 mg/kg intramuscularly), followed by sodium
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940 POVZHITKOV ET AL.
PROSTAGLANDIN RETROPERFUSION IN ACUTE ISCHEMIA
lACC Vol. 3. No.4
April 1984:939-47
pentobarbital anesthesia (25 mg/kg intravenously). After
endotracheal intubation, ventilation was maintained with a
respirator (Harvard Apparatus Co.) using a mixture of 95%
oxygen and 5% carbon dioxide. Heparin (10,000 IU, intra-
venously) was given prior to instrumentation and then sup-
plemented (3,000 IU) every 2 hours. A continuous intra-
venous infusion of physiologic saline solution was maintained
at a rate of 100 to 120 cc/min throughout the experiments.
Under fluoroscopic control, catheters were placed into the
ascending aorta, left ventricle and pulmonary artery. After
selective coronary angiography, a balloon-tipped catheter
was positioned in the proximal left anterior descending coro-
nary artery as described previously (13). A special retro-
perfusion autoinflatable balloon catheter was inserted under
fluoroscopic control into the great cardiac vein through the
left internal jugular vein (6).
Aortic and left ventricular blood pressure tracings (with
magnified left ventricular end-diastolic pressure) were ob-
tained using Statham P23Db transducers and monitored on
a physiologic recorder (model VRI2, Electronics for Medi-
cine). The first derivative of left ventricular pressure (dP/dt)
was derived by electrical differentiation. Cardiac output was
determined using the thermodilution method (Cardiac Out-
put Computer model 9520, American Edwards Laborato-
ries), and cardiac index and systemic vascular resistance
were calculated. Electrocardiograms were also monitored
on a V4 equivalent lead. Arterial blood was sampled for
routine blood gas determinations.
Regional left ventricular wall motion studies. Two-
dimensional echocardiography (ATL Mark Ill) was em-
ployed for sequential quantitative evaluation of left ven-
tricular function using the approach described by Wyatt
et al. (14). Images of five short-axis as well as long-axis
left ventricular cross sections were obtained in each dog.
Standardized computer-aided subdivision of each of the short-
axis cross sections into eight equal segments and analysis
of segmental endocardial wall motion were based on a fixed
referencing system using the endocardial geometric center
of the section (15). Sectional and segmental systolic frac-
tional area changes were used as indexes of contractile
function.
Detailed echographic study in ischemic and remote zones
concentrated on the short-axis cross section at a low left
ventricular level (near the apex) which generally exhibits
profound ischemic injury after acute proximal left anterior
descending coronary artery occlusion, and which is also
most difficult to treat with interventions. On the basis of
prior investigations, segments with an abnormal fractional
area change of less than 20% at 30 minutes after the coronary
occlusion were considered ischemic, and their average change
from the control period was also studied and at 3 hours after
occlusion. Usually, fractional area changes were less than
20% in two to four octants in each short-axis section. The
systolic fractional area change of two segments most remote
from the ischemic region was averaged to characterize con-
traction of the nonischemic myocardium. Left ventricular
volumes and ejection fraction were reconstructed as pre-
viously described (14).
Pathologic study. After the study was completed, each
dog heart was excised and cut into transverse I cm thick
slices, parallel to the atrioventricular (AV) groove. Alternate
slices were then incubated in triphenyltetrazolium chloride
(16) or fixed in Carnoy's solution, which preserves tissue
glycogen. Study of adjacent surfaces of triphenyltetrazolium
chloride-stained slices and periodic acid-Schiff (PAS)-stained
giant histologic sections of Carnoy's fixed tissue provided
comparison of areas of necrosis and ischemia at different
levels of the ventricle. Infarct size and extent of the ischemic
zone in giant histologic sections were measured by planim-
etry (16).
Synchronized retroperfusion system. The synchro-
nized retroperfusion system (Fig. 1) was used to deliver
arterial blood alone or with prostaglandin E1 into regional
coronary veins. The arterial blood was shunted from the
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Figure 1. Schematic diagram of the experimental
synchronized retroperfusion system. Arterial blood
is shunted from the brachial artery into the great
cardiac vein and regional anterior interventricular
(A.I.) coronary vein that adjoin the left anterior
descending (LAD) coronary artery. The latter is
occluded by means of an intracoronary balloon cath-
eter to create a zone of acute ischemia to be treated
by retroperfusion. Arterial blood is pumped by means
of an electrocardiographic synchronized gas-ac-
tuated bladder pump that propels blood in retrograde
manner during diastole through a special autoin-
flatable balloon catheter (SRP) into the coronary
vein. The retroperfusion flow rate is monitored by
means of an electromagnetic flowmeter (EM FLOW)
probe. The site of infusion of prostaglandin E1 is
also shown.
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Table 1. Hemodynamic Values During 3 Hours of Left Anterior Descending Coronary Artery Occlusion in Three Groups of Closed
Chest Dogs
HR SBP LVEDP dP/dt max CI SVR
Preocclusion
Group A 81 ± 5 120 ± 4 4.3 ± 0.9 1433 ± 96 2.84 ± 0.19 2561 ± 222
Group B 81 ± 6 126 ± 6 3.2 ± 0,6 1672 ± 138 2.97 ± 0.26 2735 ± 367
Group C 102 ± 8 112 ± 5 8.6 ± 0.8 1671 ± 172 2.79.± 0.47 2667 ± 290
30 minutes' occlusion
Group A 98 ± 4* 118 ± 4 10,9 ± 1.9* 1227 ± 58* 2.26 ± 0.12* 3157 ± 290*
Group B 91 ± 8 126 ± 4 7.9 ± 1.3* 1564 ± 83 2.45 ± 0.26* 2870 ± 263
Group C 109 ± 7 114 ± 5 14.6 ± 1.6* 1296 ± 169* 2.35 ± 0.23* 3203 ± 337*
3 hours occlusion
Group A 124 ± 5*1' III ± 3 0.85 ± 0.9*1' 1449 ± 79t 2.30 ± 0.24* 4226 ± 346*1'
Group B 126 ± 4*1' 123 ± 3 0.92 ± 0.5*1' 1597 ± 94 2.03 ± 0.13*1' 3636 ± 262*1'
Group C 125 ± 9*1' 118 ± 3 15.3 ± 2.1* 1238 ± 203* 1.78 ± 0.09*t 4226 ± 346*1'
Values are mean values ± standard error of the mean. *:1' p < 0.05 (* versus preocclusion ..:. versus 30 minutes of occlusion). CI = cardiac index
(liters/min per 012); dP/dt max = maximal rate of rise of left ventricular pressure (0101 Hg/s); Group A = dogs with prostaglandin E] administration and
synchronized retroperfusion (both initiated after measurements obtained 30 minutes after coronary occlusion); group B = dogs with retroperfusion alone;
group C = untreated dogs with 3 hours of occlusion; HR = heart rate (beats/min): LVEDP = left ventricular end-diastolic pressure (0101 Hg): SBP =
systolic blood pressure (0101 Hg); SVR = systemic vascular resistance (dynes's'cm ').
brachial artery into a gas-actuated bladder pump triggered
by the electrocardiogram, and was delivered during diastole,
via a special retroperfusion catheter placed within the great
cardiac vein, to the myocardial zone subserved by the left
anterior descending coronary artery. The diastolic flow in-
duces autoinflation of the balloon near the tip of the retro-
perfusion catheter, causing a brief obstruction of the great
cardiac vein, thus propelling arterial blood unidirectionally
toward the anterior intraventricular veins. During systole
retroperfusion flow was stopped by the synchronized pump,
causing collapse of the catheter balloon and facilitating
drainage of coronary venous blood through the coronary
sinus into the right atrium. The pumping system was con-
trolled to limit retroperfusion flow rates within a range of
40 to 70 cc/min, as measured by an electromagnetic f1ow-
meter (model ABC 10008 Omnicraft).
Experimental protocol. The animal preparation was
stabilized and the experiment started approximately 30 min-
utes after completion of instrumentation. The coronary ar-
tery was occluded by inflation of the intracoronary balloon
positioned immediately distal to the first diagonal branch of
the left anterior descending coronary artery. Twenty-nine
dogs that survived the first 30 minutes of coronary occlusion
were used for study of either prostaglandin E, (group A,
10 dogs), retroperfusion alone (group B, 10 dogs) or no
treatment (group C, 9 dogs). Several other dogs developed
ventricular fibrillation within the first 30 minutes after coro-
nary occlusion and were, therefore, excluded from the study.
There were no deaths between 30 minutes and 3 hours of
coronary occlusion in any of the groups.
Table 2. Two-Dimensional Echocardiographic-Derived Systolic Fractional Area Changes (FAC 1%]) in Low Left Ventricular
Short-Axis Section
Segmental FAC (%)
Preocclusion
Group A
Group B
Group C
30 minutes' occlusion
Group A
Group B
Group C
3 hours' occlusion
Group A
Group B
Group C
Sectional FAC (%)
57.1 ± 1.6
57.2 ± 1.9
55.4 ± 1.1
22.9 ± 1.5*
27.8 ± 2.9*
16.3 ± 2.7*
41.2 ± 4.0*1'
31.9 ± 1.9*1'
10.0 ± 3.3*
Ischemic Zone
53.0 ± 2.4
53.3 ± 4.1
54.3 ± 2.3
1.8 ± 3.6*
5.6 ± 6.0*
12.6 ± 6.1*
211.4 ± 5.6*j·
O.lI ± 5.7*
4.1 ± 6.9*
Remote Zone
61.4 ± 3.4
60.3 ± 2.0
52.3 ± 4.1
51.2 ± 2.9
58.0 ± 3.2
41.3 ± 3.9*
60.1 ± 4.2
57.7 ± 4.4
52.7 ± 3.5*1'
Values are mean ± standard error of mean. *, j' p < 0.05 (* versus preocclusion. l' versus 30 minutes of occlusion). Group descriptions as in Table
MP LEVEL LLV LEVEL MP LEVEL LLV LEVEL
CONTROL
5
3
CONTROL
30 min. LAO OCCLUSION
3
30 min. LAD OCCLUSION
.·1I.76cmt ...·II.I8C.... F/lC·n3"J(, .·I3.O!lan _·9.60an FAC·26.4"J(,
7
3 hours LAD OCCLUSION
8~~-.~ 5.... .
I - • 4
2 ..:
3
3 hours LAO OCCLUSION (150min. PGE.-SRPl
MP LEVEL LLV LEVEL
CONTROL
Figure 2. Representative examples of computer-derived left ven-
tricular (LV) endocardial outlines from short-axis two-dimensional
echocardiograms obtained at the midpapillary (MP) and low left
ventricular (LLV) levels during control and at 30 and 180 minutes
after occlusion of the left anterior descending (LAD) coronary
artery. The continuous lines indicate end-diastole and the dashed
lines end-systole (stippled areas). The end-diastolic (eda) and end-
systolic (esa) sectional areas are indicated. as well as the systolic
fractional area change (FAC) for the global section and its sub-
segments. A, Dog treated with prostaglandin E, retropcrfusion
(group A) showing marked reduction in fractional area change in
segments I (paradoxical bulging). 2 and 8 (severe hypokinesia).
at both the midpapillary and low left ventricular level. 30 minutes
after coronary occlusion. After 3 hours of maintained occlusion
and 2.5 hours of prostaglandin with retropcrfusion. left ventricular
size (eda) decreased and sectional and segmental fractional area
change improved significantly. B, Dog treated with retropcrfusion
alone (group B), showing substantial improvement of sectional
and segmental fractional area change at the midpapillary level, but
no significant changcs at thc low left ventricular levcl. C, Dog
with untreated coronary occlusion (group C) showing slight de-
terioration of sectional and segmcntal contraction from 30 minutes
to 3 hours of occlusion. The circle and the asterisk indicate the
end-diastolic and end-systolic center of mass, respectively. The
rcference point (anterior junction of the right ventricular free wall
and septum) is indicated by an X.
3
.d.·IO.lcm l ... ·7.16cm l FAC·29.1'l'.
7
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Coronary occlusion was maintained in all 29 dogs for 3
hours. In the two treated series (groups A and B), retro-
perfusion was started immediately following measurements
30 minutes after coronary occlusion. In group A dogs, pros-
taglandin E1 was infused continuously (25 to 30 ng/kg per
min) into the retroperfusion line by means of a multispeed
transmission pump (model 600, Harvard Apparatus Co.).
Measurements were obtained in the preocclusion control
period and at 30 and 180 minutes after the coronary occlusion.
Statistical analysis. Statistical analysis of the data con-
sisted of a Kruskal-Wallis one-way analysis of variance.
When this test indicated that a significant difference existed
among the groups (probability [p] < 0.05), the Fisher's
least significant difference test for multiple comparisons was
used to determine which of the groups were significantly
different from one another with alpha = 0.05. All of the
tests are two-tailed. The results are presented as mean values
and standard error of the mean.
Results
Hemodynamic effects of prostaglandin E, retroper-
fusion (Table 1). Because there were some differences in
baseline hemodynamic values among groups A, Band C,
only changes within each group were statistically analyzed.
In all three groups of dogs, coronary artery occlusion caused
an increase in heart rate and left ventricular end-diastolic
pressure as well as in systemic vascular resistance, while
maximal dP/dt and cardiac index decreased. Changes in
systolic blood pressure were slight. Cardiac index decreased
further up to the end of the experiments in groups B (re-
troperfusion alone) and C (no treatment), whereas dogs in
group A (prostaglandin E1 plus retroperfusion), the cardiac
output was maintained after the prostaglandin retroperfusion
treatment. Left ventricular end-diastolic pressure remained
elevated up to 3 hours of coronary occlusion in group C
(untreated dogs) but showed a dramatic decrease in both
series treated with retroperfusion (groups A and B). A slight
but statistically significant increase in maximal rate of rise
of left ventricular pressure (dP/dt max) was noted in group
A, appearing within minutes after the start of prostaglandin
E1 retroperfusion and persisting to the end of the experi-
ments. In groups Band C, there was no significant change
in dP/dt max between 30 minutes and 3 hours of coronary
occlusion.
Electrocardiographic changes. All the dogs exhibited
significant ST segment elevation after coronary occlusion.
Ectopic ventricular activity was generally observed in the
first 5 to 20 minutes after occlusion, and similar activity
occasionally reappeared after close to 3 hours of occlusion
in the untreated control dogs. In both treated groups, a trend
toward electrical stabilization became apparent within \0 to
20 minutes after initiation of retroperfusion. Sinus tachy-
cardia was observed in some dogs during the initial stage
of the pulsatile treatment.
Echocardiographic analysis of left ventricular func-
tion (Table 2, Fig. 2). Coronary artery occlusion led to
prompt and significant alterations in the echocardiographi-
cally derived index of segmental contraction, with severe
hypokinesia or dyskinesia noted in zones subserved by the
left anterior descending coronary artery, indicating profound
regional myocardial ischemia. Thirty minutes after occlu-
sion, echographic study at the low left ventricular level
section indicated a significant reduction in anterolateral wall
systolic fractional area change (from 53.0 ± 2.4 to 1.8 ±
3.6%,53.3 ± 4.\ to 5.6 ± 6.0% and 54.3 ± 2.3 to 12.6
± 6.1 % in groups A, Band C, respectively). Smaller changes
were observed in segments remote from the ischemic region.
Whereas reduced contraction could also be demonstrated in
short-axis cross sections at higher levels of the left ventricle,
these changes were not nearly as profound as those at the
midpapillary and low ventricular levels.
Further significant deterioration in ischemic zone con-
traction developed in the untreated control dogs (group C)
100 100 DCQNTROL ;I: MtSEM
r.J 30min LAD Ocel • p<O.OI r.lotlve to Control
I1I50min PGE, SRP t P<O.OI rlta.lv. to 3Om1" Figure 3. Effects of prostaglandin E1 coronary ve-80 80 LAD OCCi
nous retroperfusion (PGE,-SRP) on left ventricular
60 60 .t (LV) global and segmental function after left anterior
~ dcscending (LAD) coronary artery occlusion (Occl.).e..... Two-dimensional echocardiography was employed40 40
to derive systolic fractional area changes (FAC %)
20 20 in high papillary (HP) and low left ventricular short-
axis cross sections. ANT-LAT segment = antero-
0 0 lateral ischemic zone; M = mean; posterior segment
ANT-LAT POSTERIOR ANT-LAT POSTERIOR LV E.ECTION = remote zone; SEM = standard error of mean.
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Table 3. Myocardial Necrosis (N) as Estimated by Triphenyltetrazolium Chloride and Ischemia (I) (estimated by myocardial
glycogen depletion in a mid-left ventricular slab) and as Percent of the Total Left Ventricular Mass
Dog %1 %N N% ofl N% of LV Mass
Group A (prostaglandin E, retroperfusion)
A-I 2.5 (P) 0 0 0
A-2 13.5 (C) 0 0 0
A-3 26.2 (C) 1.5 (P) 5.8 1.3
A-4 3.0 (P) 0 0 0
A-5 29.3 (C) 7.4 (P) 25.3 5.7
A-6 19.5 (C) 7.1 (P) 36.4 5.9
A-7 40.2 (P) 4.3 (P) 10.7 3.0
A-8 16.8 (C) 2.7 (P) 15.8 1.5
A-9 29,3 (Cl 13.0 (P) 44.4 7.3
A-IO 24.5 (Cl 13.8 (C) 56.3 12.4
Mean 20.5 5.0 19.5 3.7
± SEM ± 3.8* ± 1.6* ± 6.4* ± 1.3*
Group B (retroperfusion without drug)
B-1 13.1 (P) 3.9 (P) 29.8 1.7
B-2 12.3 (P) 0.6 (P) 4.6 0.8
B-3 23.7 (C) 22.0 (C) 92.8 12.4
B-4 nla 3.1 (P) 2.9
B-5 5.9 (P) 0 0 0
B-6 18.5 (C) 15.9 (Pl 85.9 9.6
B-7 12.5 (P) 0 0 0
B-8 35.4 (Cl 29.8 (C) 84.2 16,5
B-9 11.5 (P) 0 0 0
B-IO 33.8 (P) 7.7 (P) 22.8 4.0
Mean 18.5 8.3 35.6 4.8
± SEM ± 3.5* ± 3.4* ± 13.5 ± 1.9*
Group C (occlusion without treatment)
C-I 49.1 (Cl 32.7 (C) 66.7 13.3
C-2 63.7 (C) 21.8 (C) 34.2 10.4
C-3 14.3 (C) 10.4 (C) 72.8 8.4
C-4 100.0 (C) 21.8 (C) 21.8 12.4
C-5 42.5 (C) 42,5 (C) 100.0 20.7
C-6 37.5 (Cl 11.4 (C) 30.4 5.8
C-7 33.0 (C) 9.4 (C) 28.5 4.8
C-8 14.0 (P) 3.7 (P) 26.5 2.9
C-9 42.1 (C) 18.1 (C) 43.0 4.7
Mean 44.0 19.1 47.1 9.3
± SEM ± 8.7 ± 4,1 ± 8.9 ± 1.9
* = p < 0.05 relative to Group C; C = confluent pattern; LV = left ventricular; nla = not available; P = patchy pattern; SEM = standard error
of the mean.
between 30 minutes and 3 hours of occlusion, During the
same period of maintained coronary artery occlusion, ret-
roperfusion with arterial blood only (group B) resulted in
improvements in both sectional and ischemic segment con-
traction at the midpapillary section leveL Thus, in the isch-
emic anterolateral region fractional area change increased
significantly from 13.4 ± 3,9 to 32.1 ± 10.4% (p < 0,05),
and in the remote posterior region from 53.0 ± 3.0 to 62.3
± 2.9% (p < 0.05). Yet, at the low level section of the
left ventricle where ischemic injury was most severe, re-
troperfusion alone failed to correct the profound antero-
lateral segmental dysfunction (Table 2),
In the prostaglandin £, retroperfusion group. improve-
ments in both sectional and segmental contraction were ev-
ident at 3 hours of occlusion (Table 2, Fig. 3). Significant
improvement in the anterolateral ischemic segment systolic
fractional area change was observed even at the low left
ventricular level (from 1.8 ± 3.6% at 30 minutes after
occlusion to 29.4 ± 5.6% after 2'/2 hours of prostaglandin
retroperfusion), although preocclusion levels of contraction
were not reached, In the posterior ventricular wall segments,
contraction which was slightly decreased at 30 minutes post-
occlusion returned to near preocclusion values. Correspond-
ing improvements were demonstrated in global sectional
lACC Vol. 3, No.4
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contraction and in left ventricular ejection fraction in group
A, compared with no change or further deterioration in
group C,
Myocardial infarct size and zone of ischemia (Table
3, Fig. 4). Compared with untreated control dogs (group
C), dogs with prostaglandin E1 retroperfusion (group A)
Figure 4. Examples of morphologic findings in dogs studied. a,
Periodic acid-Schiff (PAS)-stained giant histologic section from a
control dog (Group C, untreated 3 hour occlusion), showing a
large confluent region of ischemia (i) as indicated by glycogen
loss, b, Triphenyltetrazolium chloride stain of contiguous surface
of adjacent slice of myocardium, showing a large confluent region
of necrosis (n) (lack of staining). c, PAS-stained section from a
dog treated with prostaglandin E1 and coronary venous retroper-
fusion (group A), Glycogen loss (ischemia) (i) is less extensive
than in the control dog and patchy, d, Triphenyltetrazolium chlo-
ride-stained contiguous surface of adjacent slice of myocardium
showing a small patchy region of necrosis (n).
a
exhibited significantly smaller infarct size after 3 hours of
coronary occlusion (9,3 ± 1.9% of the left ventricle, versus
3.7 ± 1.3%, P < 0,05), Macroscopic examination of the
stained ventricular slabs from the treated groups often re-
vealed patchy and unevenly distributed subendocardial ne-
crotic areas, predominantly at the apical and low papillary
levels, whereas slabs obtained from untreated dogs with 3
hours of occlusion (group C) generally demonstrated wide-
spread confluent infarcts. The ischemic glycogen-depleted
area measured in a mid-left ventricular slice was also sig-
nificantly smaller in size in group A than in group C
(20.5 ± 3,8 versus 44.0 ± 8,7%, p < 0.05), suggesting
a decrease in ischemia as a result of the prostaglandin E1
retroperfusion treatment.
Discussion
Severe regional left ventricular dysfunction supervened
very rapidly after proximal left anterior descending coronary
artery occlusion in closed chest dogs. The jeopardized dys-
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functioning zone was clearly delineated by two-dimensional
echocardiography in short-axis cross sections of the ventri-
cle, and this ischemic zone essentially corresponded to the
extent of myocardial glycogen depletion outlined in equiv-
alent slices of the heart (17). It is now widely appreciated
that acute myocardial infarction generally develops as a
result of a thrombotic coronary artery occlusion, and that
in the absence of adequate preexisting collateral vessels,
dysfunction sets in rapidly and regional myocardium at risk
will be irreversibly damaged if it is not possible to institute
an efficacious intervention. To be effective, such treatment
must reach the jeopardized zone in sufficient measure and
in time to ensure ischemic tissue survival.
Re-establishment ofadequate coronary blood flow and
myocardial perfusion. This is deemed the treatment of
choice, and new nonsurgical and surgical reperfusion tech-
niques are being applied. Yet, even when these newer treat-
ments are used, pharmacologic support or circulatory as-
sistance may be essential to maintain viability pending
achievement of effective reperfusion (18). Unfortunately,
access to the most profoundly ischemic segment of the heart
distal to the coronary occlusion is frequently limited, so that
direct beneficial effects of administration of pharmacologic
agents may be minimal. The pulsatile coronary venous ret-
roperfusion technique, previously examined by us and mod-
ified for the current study, represents an alternate mode of
delivery of blood and agents to the endangered ischemic
myocardium, along with potentially enhanced washout of
metabolites. Although retroperfusion with arterial blood was
shown to provide significant benefits, it has been the ex-
perience that the most distal myocardium beyond a left
anterior descending coronary artery occlusion (near the left
ventricular apex) may not be salvaged. We hypothesized
that supplemental use of prostaglandin E, might enhance
the retroperfusion performance and possibly provide salvage
even in this most profoundly ischemic region.
Benefits of prostaglandin E) retroperfusion. Each of
the three series of dogs in the present investigation (prosta-
glandin E, retroperfusion, retroperfusion alone and no treat-
ment) developed severe ischemic dysfunction at 30 minutes
after occlusion, following which the protocol called for dif-
ferential treatment. In the dogs without treatment, function
in the ischemic zone deteriorated further after up to 3 hours
of occlusion, particularly in the profoundly injured antero-
lateral segments of lower ventricular cross sections, al-
though contractile derangements were also seen at higher
levels of the left ventricle. With 2Yz hours of prostaglandin
retroperfusion during maintained coronary occlusion, sig-
nificant improvements were demonstrated by echocardiog-
raphy even in the most profoundly ischemic area, and this
was reflected in the significant reduction in infarct size com-
pared with that in the untreated series, along with evidence
of reduction in the extent of ischemia. Treatment with ar-
terial blood retroperfusion alone during an equivalent period
confirmed previous evidence of significant and prompt im-
provement of function and reduction of infarct size in most
regions of the left ventricle, except in the most profoundly
ischemic zone near the apex. Thus, prostaglandin supple-
mentation was shown to provide additional benefits during
acute myocardial ischemia in addition to those experienced
with arterial blood retroperfusion alone.
Mechanism of prostaglandin E) retroperfusion. The
action of prostaglandin E 1 delivered by retroperfusion into
the ischemic zone may be associated with one or several of
the reported direct myocardial mechanisms. Thus, prosta-
glandin-induced enhancement of myocardial contractility and
reduction of preload (5,6,19) might be responsible for the
observed improved ischemic zone contraction and lowered
left ventricular end-diastolic pressure. Review of effects of
prostaglandin E, on the coronary circulation suggests that
this drug produces coronary vasodilation (3,20-22) as well
as general relaxation of the vascular smooth muscle (23).
Experimental data also indicate that prostaglandin Ej might
increase myocardial contractile force, reduce left ventricular
end-diastolic length and increase cardiac output (3).
The effects of prostaglandin E, on the preservation of
acutely ischemic myocardium have been studied in different
species. Thus, when prostaglandin E, was administered in-
travenously in cats with coronary occlusion, there was a
significant decrease in infarct size and improved hemody-
namics were demonstrated (24). The mechanisms and ef-
fects of prostaglandins in various physiologic settings and
myocardial ischemia remain controversial, presumably be-
cause investigators have used different species, different
protocols and a wide range of drug dosages. Nevertheless,
prostaglandin E, seems to have a general beneficial action
in acute myocardial ischemia. The apparent ability of the
drug to improve myocardial perfusion through coronary
vasodilation and its beneficial hemodynamic effects have
stimulated initial clinical trials in patients with unstable an-
gina pectoris and acute myocardial infarction (19).
Clinical implications. The clinical potentials indicated
by this study transcend the use of prostaglandin E, retro-
perfusion. Our evidence suggests that synchronized coro-
nary venous retroperfusion may effectively deliver drugs to
the acutely ischemic myocardium for maintenance of its
function and viability. A series of pharmacologic agents
previously considered beneficial in the setting of acute
ischemia, particularly those with direct myocardial effects,
should now be re-examined with more appropriate coronary
venous delivery and consequently enhanced local drug
concentration.
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